NO996310D0 - Sammensetninger og fremgangsmåter for å redusere respirasjonsdepresjon og ledsagende bivirkninger av mu-opioide forbindelser - Google Patents

Sammensetninger og fremgangsmåter for å redusere respirasjonsdepresjon og ledsagende bivirkninger av mu-opioide forbindelser

Info

Publication number
NO996310D0
NO996310D0 NO996310A NO996310A NO996310D0 NO 996310 D0 NO996310 D0 NO 996310D0 NO 996310 A NO996310 A NO 996310A NO 996310 A NO996310 A NO 996310A NO 996310 D0 NO996310 D0 NO 996310D0
Authority
NO
Norway
Prior art keywords
respiratory depression
animal
reducing
compositions
methods
Prior art date
Application number
NO996310A
Other languages
English (en)
Other versions
NO996310L (no
Inventor
Kwen-Jen Chang
Robert W Mcnutt Jr
Hugh O Pettit
Michael J Bishop
Original Assignee
Delta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Pharmaceuticals Inc filed Critical Delta Pharmaceuticals Inc
Publication of NO996310D0 publication Critical patent/NO996310D0/no
Publication of NO996310L publication Critical patent/NO996310L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO996310A 1997-07-03 1999-12-17 Sammensetninger og fremgangsmÕter for Õ redusere respirasjonsdepresjon og ledsagende bivirkninger av mu-opioide forbindelser NO996310L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/887,312 US5985880A (en) 1996-06-05 1997-07-03 Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
PCT/US1997/017852 WO1999001033A1 (en) 1997-07-03 1997-10-01 Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds

Publications (2)

Publication Number Publication Date
NO996310D0 true NO996310D0 (no) 1999-12-17
NO996310L NO996310L (no) 2000-02-22

Family

ID=25390891

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996310A NO996310L (no) 1997-07-03 1999-12-17 Sammensetninger og fremgangsmÕter for Õ redusere respirasjonsdepresjon og ledsagende bivirkninger av mu-opioide forbindelser

Country Status (23)

Country Link
US (5) US5985880A (no)
EP (1) EP1003373B1 (no)
JP (1) JP2002502432A (no)
KR (1) KR20010014279A (no)
CN (1) CN1165308C (no)
AT (1) ATE259226T1 (no)
AU (1) AU756120B2 (no)
BR (1) BR9714739A (no)
CA (1) CA2294924C (no)
CZ (1) CZ9904694A3 (no)
DE (1) DE69727593D1 (no)
HU (1) HUP0003842A3 (no)
IL (1) IL133600A0 (no)
IS (1) IS5309A (no)
NO (1) NO996310L (no)
NZ (1) NZ501817A (no)
PL (1) PL337578A1 (no)
RU (1) RU2201231C2 (no)
SI (1) SI20245A (no)
SK (1) SK185399A3 (no)
TR (1) TR199903324T2 (no)
TW (1) TW513426B (no)
WO (1) WO1999001033A1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985880A (en) * 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
CN1434704A (zh) * 1999-12-16 2003-08-06 三叉技术有限责任公司 延长其受体负荷剂量的治疗剂释放的系统和方法
SE0001207D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
US7125718B2 (en) 2000-05-24 2006-10-24 University Of Maryland Biotechnology Institute Method for introducing and expressing genes in animal cells, and bacterial blebs for use in same
WO2002094794A1 (en) 2001-05-18 2002-11-28 Astrazeneca Ab 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
MXPA04002813A (es) * 2001-09-25 2005-06-06 Ardent Pharmaceuticals Inc Diarilmetilpiperazina enantiomericamente pura y metodos para usarla.
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
EP1450807B1 (en) * 2001-10-29 2013-12-25 Versi Group, LLC Method of treating depression with delta receptor agonist compounds
AU2003214800A1 (en) * 2002-01-02 2003-07-24 Ardent Pharmaceuticals, Inc. Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
US8476280B2 (en) * 2002-05-09 2013-07-02 Versi Group, Llc Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
ES2372047T3 (es) * 2002-12-04 2012-01-13 Virginia Commonwealth University Agentes antidrepanocíticos.
US7314880B2 (en) * 2003-01-02 2008-01-01 Mount Cook Biosciences, Inc. Cardioprotective delta opioid receptor agonists and methods of using same
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7119208B2 (en) * 2003-12-03 2006-10-10 Virginia Commonwealth University Anti-sickling agents
KR101234421B1 (ko) 2004-08-02 2013-02-18 아스트라제네카 아베 디아릴메틸 피페라진 유도체, 이의 제조 방법 및 용도
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
MX2007010833A (es) 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US7683168B2 (en) * 2005-04-14 2010-03-23 Mount Cook Bio Sciences, Inc. Compositions of novel opioid compounds and method of use thereof
GB0606124D0 (en) * 2006-03-28 2006-05-03 Reckitt Benckiser Healthcare Buprenorphine derivatives and uses thereof
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
JP2011500686A (ja) * 2007-10-18 2011-01-06 アイコ バイオテクノロジー オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤
JP6279547B2 (ja) * 2012-04-17 2018-02-14 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
IL286391B (en) 2015-12-22 2022-08-01 Zogenix International Ltd Penfluramine preparations and methods for their preparation
US20170174614A1 (en) 2015-12-22 2017-06-22 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
EP4201427A1 (en) 2016-08-24 2023-06-28 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
CA3207668A1 (en) 2017-04-30 2018-11-08 Dmk Pharmaceuticals Corporation An opioid for use to reduce and/or treat drug addiction
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2630435A (en) * 1948-09-09 1953-03-03 Burroughs Wellcome Co N-benzohydryl-n-methyl piperazines and process of preparing same
US4167574A (en) * 1978-03-13 1979-09-11 Janssen Pharmaceutica, N.V. N-phenyl-N-(4-piperidinyl)amides
US4518711A (en) * 1983-05-16 1985-05-21 Gibson-Stephens Institute Conformationally constrained cyclic enkephalin analogs with delta receptor specificity
GB8320701D0 (en) * 1983-08-01 1983-09-01 Wellcome Found Chemotherapeutic agent
PH24752A (en) * 1987-04-16 1990-10-01 Lilly Co Eli Piperidine opioid antagonists
US4816586A (en) * 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
DK0409406T3 (da) * 1989-06-19 1994-02-07 Wellcome Found Arylsubstituerede aminderivater, der er anvendelige ved cancerterapi
JPH03163030A (ja) * 1989-08-28 1991-07-15 Arizona Technol Dev Corp アヘン剤活性を選択的に強化し、アヘン剤耐性と依存性を軽減するための組成物と方法
EP0458160A3 (en) * 1990-05-25 1992-03-18 Sociedad Espanola De Especialidades Farmaco-Terapeuticas, S.A. Substituted diphenylmethane derivatives as analgesic or anti-inflammatory agents
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
NZ240863A (en) * 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5681830A (en) 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5807858A (en) * 1996-06-05 1998-09-15 Delta Pharmaceutical, Inc. Compositions and methods for reducing respiratory depression
US5574159A (en) * 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
CA2168432C (en) 1993-07-30 2004-03-23 Kwen-Jen Chang Piperazine compounds used in therapy
IT1270612B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Derivati eterociclo-condensatori di morfinoidi
US5753516A (en) * 1995-02-03 1998-05-19 Heagy; Wyrta E. Screening method for ligands of the EBI-1 receptor
IT1275433B (it) * 1995-05-19 1997-08-07 Smithkline Beecham Farma Derivati di diarildiammine
IT1277597B1 (it) * 1995-09-15 1997-11-11 Smithkline Beecham Spa Derivati di diarilalchenilammina
GB9709972D0 (en) 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
GB9804734D0 (en) 1998-03-05 1998-04-29 Pfizer Ltd Compounds

Also Published As

Publication number Publication date
US20050255151A1 (en) 2005-11-17
CN1262600A (zh) 2000-08-09
NZ501817A (en) 2002-02-01
EP1003373B1 (en) 2004-02-11
NO996310L (no) 2000-02-22
KR20010014279A (ko) 2001-02-26
AU4806697A (en) 1999-01-25
IL133600A0 (en) 2001-04-30
DE69727593D1 (de) 2004-03-18
CN1165308C (zh) 2004-09-08
CA2294924C (en) 2010-12-21
PL337578A1 (en) 2000-08-28
RU2201231C2 (ru) 2003-03-27
US20020111359A1 (en) 2002-08-15
TW513426B (en) 2002-12-11
US20080193383A1 (en) 2008-08-14
IS5309A (is) 1999-12-17
US6300332B1 (en) 2001-10-09
BR9714739A (pt) 2000-07-25
HUP0003842A3 (en) 2001-12-28
EP1003373A1 (en) 2000-05-31
JP2002502432A (ja) 2002-01-22
ATE259226T1 (de) 2004-02-15
WO1999001033A1 (en) 1999-01-14
TR199903324T2 (xx) 2000-09-21
SI20245A (sl) 2000-12-31
CA2294924A1 (en) 1999-01-14
AU756120B2 (en) 2003-01-02
SK185399A3 (en) 2001-08-06
US6919350B2 (en) 2005-07-19
EP1003373A4 (en) 2000-09-20
CZ9904694A3 (cs) 2002-03-13
US5985880A (en) 1999-11-16
HUP0003842A1 (hu) 2001-04-28

Similar Documents

Publication Publication Date Title
NO996310D0 (no) Sammensetninger og fremgangsmåter for å redusere respirasjonsdepresjon og ledsagende bivirkninger av mu-opioide forbindelser
IL129410A (en) Unit dose, sustained release oral dosage form of an opioid analgesic and a method for the preparation thereof
NZ319531A (en) An analgesic synergistic composition containing a sub-analgesic dose of a mu opioid agonist and a kappa-2 opiod agonist
WO2000021515A3 (en) Intranasal codeine for the rapid suppression of cough and rapid relief of pain
NZ508526A (en) Opioid formulations for treating pain
EP1685839B8 (en) Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist
ATE143599T1 (de) Codeinonderivate und ihre pharmazeutische verwendung
MXPA02007690A (es) Composiciones de liberacion controlada que contienen agonista y antiagonista de opioide.
NZ324887A (en) Piperazine and piperidine compounds with analgesic effect
WO2001013909A3 (en) Compositions and methods for treating opiate intolerance
AU2223095A (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
NZ332215A (en) Transdermally administered dextromethorphan as antitussive agent
GB9721746D0 (en) Compositions
EP1219624A4 (en) REMEDIES AGAINST NEUROPATHIC PAIN AND ANIMAL MODELS OF NEUROPATHIC PAIN
ATE212550T1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
EP0906757A3 (en) Analgesic composition comprising moxonidine and an opioid analgesic agent
EP1197227A4 (en) METHOD FOR ADMINISTERING MEDICINAL PRODUCTS WITH BINDING AFFINITY TO PLASMA PROTEIN AND USE OF THE COMPOSITION IN THE METHOD
CA2400578A1 (en) Controlled-release compositions containing opioid agonist and antagonist
MX9800809A (es) Procedimiento para preparar formas de dosis solidas de dosis muy bajas del farmaco.
EP0761209A3 (en) Controlled release formulations of ranitidine
AU5981200A (en) Transdermal therapeutic system for administering a calcium antagonist
EP0097953A3 (en) Synergistic compositions of nalbuphine and non-narcotic analgesic compounds
AU8900498A (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
ECSP961835A (es) Nuevo procedimiento
SE9802555D0 (sv) New pharmaceutical preparation and method

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application